Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04901169 · ClinicalTrials.gov registry record · Phase 2
Angiotensin II in Liver Transplantation
A Phase 2 study of Liver Transplant, Complications and Vasoplegia, sponsored by University of California, San Francisco.
- Active
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT04901169 is a Phase 2 study of Liver Transplant, Complications and Vasoplegia that is active but no longer recruiting, run by University of California, San Francisco. The registered enrollment target is 50 participants, below the 528-participant average among 7 other Liver Transplant, Complications trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04901169, a Phase 2 study of Liver Transplant, Complications and Vasoplegia, is active but no longer recruiting, sponsored by University of California, San Francisco.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the efficacy and safety of Angiotensin II as a second-line vasopressor (drug that raises the blood pressure) during liver transplantation.
Conditions Studied
Interventions
- DRUG Saline
- DRUG Angiotensin II
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-06-28 |
| Est. Completion | 2027-03-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04901169
The ClinicalTrials.gov registry entry for NCT04901169 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 528-participant average among 7 other Liver Transplant, Complications trials with a reported enrollment target (91% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Liver Transplant, Complications appearing as the primary indexed condition, and to 2 interventions - of which Saline is the first listed.
NCT04901169 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04901169 about?
NCT04901169 is a clinical study titled "Angiotensin II in Liver Transplantation". The purpose of this study is to determine the efficacy and safety of Angiotensin II as a second-line vasopressor (drug that raises the blood pressure) during liver transplantation.
What is the current status of trial NCT04901169?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2022-06-28. Estimated completion is 2027-03-18.
What conditions does trial NCT04901169 study?
This clinical trial studies the following conditions: Liver Transplant, Complications, Vasoplegia.
What interventions are being tested in trial NCT04901169?
The interventions under investigation include: Saline (DRUG), Angiotensin II (DRUG).
Who is sponsoring clinical trial NCT04901169?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04901169 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Transplant, Complications
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation
RECRUITING · Phase 2
-
HEalth Advocate for Liver Transplant - Pilot
RECRUITING · NA
-
Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs
RECRUITING
-
Technology Enabled Strategies to Promote Treatment Adherence in Liver Transplant
RECRUITING · NA
-
HEalth Advocate for Liver Transplantation: Improving Transition of Care for Adolescent Liver Transplant Recipients
RECRUITING · NA
-
Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)
RECRUITING · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.